Chris
@ChrisCC92
Followers
234
Following
5K
Media
164
Statuses
1K
Double-board certified in & Associate Professor of Medical Oncology and Internal Medicine🎒 | Wit beyond measure is man’s greatest treasure 📚
Joined July 2009
Stage III N2 NSCLC deserves rethinking. In the CheckMate 77T exploratory analysis, perioperative nivolumab + chemotherapy delivers meaningful gains even in N2 and multistation N2 disease: • 1-yr EFS 70% vs 45% (HR 0.46) • pCR 22% vs 5.6% • High resection and lobectomy rates
nature.com
Nature Cancer - Provencio and colleagues reported the exploratory efficacy outcomes and safety results from the CheckMate 77T phase 3 trial in patients with stage III resectable non-small-cell lung...
4
27
77
Premenopausal HR+/HER2+ eBC – Adjuvant ET • RD after NAT → OFS + AI • pCR after NAT → risk-adapted – Stage III → OFS + AI – Stage I–II → AI or TAM ± OFS • Upfront surgery → baseline stage-driven ET Principle: RD = ER-dependent, chemo-resistant → needs ET
0
32
69
Translating Tumor Biology to the Clinic: Tackling Heterogeneity and Resistance in Breast Cancer. Terrific presentation by Aleix Prat 🤓
0
0
0
Precision oncology promise in the management of pancreatic acinar cell carcinoma European Journal of Cancer https://t.co/hPJqXQEjZZ 👉PACC lacks KRAS, TP53, & CDKN2A mutations 👉Options for targeted 💊, BRAF V600E mutations, NTRK fusions, & ALK.. 👉NGS profiling warranted
1
16
57
Results of cohort 3 #BREAKWATER FOLFIRI + encorafenib + cetuximab for newly dx'd #BRAFV600E MT #colorectal #cancer 👉ORR: 64.4% vs. 39.2% 👉60% with liver mets 👉Premature OS but trend (HR = 0.49); PFS: Pending 👉No dramatic increase in SAE 👉 Therefore, you can use FOLFOX or
1
30
89
Hi everyone! Been a while, but back today with a teaching video on palliative RT for GI cancers. IMO palliative RT can be v effective, but is underutilized. Here is 13 min on indications, regimens, common q's re: palliative RT by GI site. Slides & full video link below 🧵1/5.
6
73
255
📙Organ Preservation for GEJ and Gastric Cancers: Ready for Primetime? ASCO Educational book 👉 https://t.co/V5w8J7eiER
#cancer #oncology #MedX #gastric #GI26 @OncoAlert
0
45
119
Art of Oncology The Power of “I Don’t Know” @JCO_ASCO
https://t.co/B7UirjKSRA 😄I fully agree... @myESMO
3
43
195
Stay informed about key cancer awareness dates in 2026. Our calendar includes all awareness months and important dates to remember. Explore more about oncology conferences, top trials, and reactions from oncologists: https://t.co/VJu7Mfmopy
#LARVOL #Oncology #CancerCare
5
18
40
Proud to see out on @CCR_AACR our last article from the AURORA molecular program, focusing on gene fusions Acquired gene fusions (especially ESR1 fusions) are associated with poor prognosis and more aggressive disease in ER+/HER2-neg BC @OncoAlert
https://t.co/VbXAGmHNKj
1
11
30
Plan your 2026 conference schedule better with @Larvol. Here is our list of the Top 25 Oncology Conferences worldwide. Explore more about oncology conferences, top trials, and reactions from oncologists: https://t.co/VJu7Mfmopy
#LARVOL #Oncology #CancerResearch #CancerData
1
23
70
🧓🎯 Locally advanced rectal cancer in older patients (≥70 y) and unfit for ChT: SOFT study ☢️ SCRT (5×5 Gy) + delayed surgery 📊 Downstaging 62% | R0 resection 94% | pCR 5.7% ✅ Acceptable toxicity & low mortality ➡️ SCRT: pragmatic alternative in frail patients 🔗
1
35
80
Physical activity decreases cancer burden by alleviating immunosenescence-related inflammation & improving overall immunity @CellRepMed
https://t.co/hMLJjBPGNP 👉Exercise counteracts inflammation and improves overall immunity 👉Physical activity decreases the risks of all-cancer
1
13
45
🧬🔬 Claudin 18.2 in cancer care — pathologist’s view 📘 Systematic review: biology, IHC assays, scoring & pre-analytics 🎯 Actionable/companion biomarker for T-T ⚠️ Membrane scoring, fixation & clone choice are critical ➡️ Standardisation is key for reliable patient seleccionó
1
18
57
A nomogram for predicting overall survival in advanced hepatocellular #carcinoma patients receiving #radiotherapy combined with targeted therapy, published in Transl Cancer Res. 👉Read it before your patients: https://t.co/MUVpQ6dZrY
1
4
13
Completely agree. This is exactly the concept behind the design of ATENEA, our ongoing clinical trial.
@DrewMoghanaki @MARIANOPROVENCI @gecp_org For me it’s about eliminating the notion of « stage III » and talking about micro metastatic disease where we prioritize a systemic treatment first and then decide together on the most optimal form of local therapy and also whether such local therapy is even necessary.
2
7
31
how to make friends in a new city: > say yes to everything for the first 3 months > ask locals what they like to do in the area - you can follow their recs for inspiration > when you vibe with someone, ask to hang. don't wait for them to initiate!! > try multiple communities &
185
6K
79K
